DISP-12. Diagnostic clues to central nervous system (CNS) tumors in children with developmental delay: a case for system-level change

Abstract Diffuse midline glioma (DMG), H3 K27M, is an aggressive WHO grade IV CNS lesion of the pons, thalamus, or spine with a median survival of 8-12 months, predominantly in children.1-6 While pontine tumors often present with cranial nerve deficits, long tract signs, and cerebellar dysfunction,6-8 presentation in children with developmental delay can be subtle. Early signs, such as gait abnormalities or impaired speech, may be misattributed to underlying neurodevelopmental disorders. This case highlights proposed systemic changes to improve early detection of primary CNS tumors, emphasizing known risk factors and access to care. We present a 4-year-old girl with autism spectrum disorder, developmental delay, and longstanding gait abnormalities who presented with two weeks of worsening gait, refractory to six months of physical therapy. Since walking began at 17 months, she exhibited a left foot drop and limited echolalic speech. Examination revealed bilateral lower extremity hyperreflexia, a left Babinski sign, and a wide-based, left-leaning shuffling gait. Neuroimaging identified a pontine mass, with biopsy confirming DMG, H3 K27M, CNS WHO grade IV. She died 2.5 months later. This case highlights the diagnostic challenge of distinguishing neurodevelopmental disorders from neurological malignancies. In nonverbal children without regular medical care, diagnosis is often delayed. Thus, clinicians must maintain a high index of suspicion for neurological pathology in children with developmental delays and focal neurological signs, particularly when healthcare access is limited. Neuroimaging indications include focal neurologic symptoms and developmental regression. Improving early detection and management requires broader access to evaluation and imaging, supported by public education, primary and specialty care access, and streamlined referral systems. While DMG remains incurable, earlier diagnosis may allow families meaningful time together and advance research.

Authors

Institutions

Publication Details

Journal
Neuro-Oncology
Published
2025-11-01
DOI
https://doi.org/10.1093/neuonc/noaf201.0773
Primary Topic
Glioma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

DISP-12. Diagnostic clues to central nervous system (CNS) tumors in children with developmental delay: a case for system-level change

Ai Sakonju, Nynoshka Bassatt Cabrera, Richmond Mensah
Neuro-Oncology
Glioma Diagnosis and Treatment
article

DISP-12. Diagnostic clues to central nervous system (CNS) tumors in children with developmental delay: a case for system-level change

Ai Sakonju, Nynoshka Bassatt Cabrera, Richmond Mensah
article en

Abstract

Abstract Diffuse midline glioma (DMG), H3 K27M, is an aggressive WHO grade IV CNS lesion of the pons, thalamus, or spine with a median survival of 8-12 months, predominantly in children.1-6 While pontine tumors often present with cranial nerve deficits, long tract signs, and cerebellar dysfunction,6-8 presentation in children with developmental delay can be subtle. Early signs, such as gait abnormalities or impaired speech, may be misattributed to underlying neurodevelopmental disorders. This case highlights proposed systemic changes to improve early detection of primary CNS tumors, emphasizing known risk factors and access to care. We present a 4-year-old girl with autism spectrum disorder, developmental delay, and longstanding gait abnormalities who presented with two weeks of worsening gait, refractory to six months of physical therapy. Since walking began at 17 months, she exhibited a left foot drop and limited echolalic speech. Examination revealed bilateral lower extremity hyperreflexia, a left Babinski sign, and a wide-based, left-leaning shuffling gait. Neuroimaging identified a pontine mass, with biopsy confirming DMG, H3 K27M, CNS WHO grade IV. She died 2.5 months later. This case highlights the diagnostic challenge of distinguishing neurodevelopmental disorders from neurological malignancies. In nonverbal children without regular medical care, diagnosis is often delayed. Thus, clinicians must maintain a high index of suspicion for neurological pathology in children with developmental delays and focal neurological signs, particularly when healthcare access is limited. Neuroimaging indications include focal neurologic symptoms and developmental regression. Improving early detection and management requires broader access to evaluation and imaging, supported by public education, primary and specialty care access, and streamlined referral systems. While DMG remains incurable, earlier diagnosis may allow families meaningful time together and advance research.

Neuro-OncologyVol. 27(Supplement_5)
SUNY Upstate Medical University (US)
Openalex Percentile: Top 51%
Glioma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

DISP-12. Diagnostic clues to central nervous system (CNS) tumors in children with developmental delay: a case for system-level change — Ai Sakonju, Nynoshka Bassatt Cabrera, et al. · Neuro-Oncology (2025) | TGRS Research Map | TGRS